# Core D - Genomics

> **NIH NIH U19** · EMORY UNIVERSITY · 2022 · $2,841,208

## Abstract

Project Summary – Core D
The ability of RNA viruses to rapidly mutate and develop resistance to medical countermeasures is a
considerable barrier to the development of broadly acting antivirals. Viral genotyping can help determine the
mechanistic basis and degree of barrier to the development of antiviral resistance. The Genomics Core will
provide accurate, timely, and reproducible viral whole genome sequencing data for all Projects in the Antiviral
Countermeasures Development Center (AC/DC). Dr. Alex Greninger, Core Leader, is Assistant Director at the
UW Virology Lab and has over 15 years of experience in viral genomics and molecular testing. Using a
combination of different sequencing approaches including metagenomic, hybridization capture, and amplicon
tiling combined with a clinical trials-grade quality management infrastructure, our laboratory has built a robust
and automated wet-lab and dry-lab pipeline for the recovery of RNA virus genomes. With the Center’s focus on
developing and characterizing broadly acting RNA polymerase-directed antivirals against a variety of RNA
viruses, the Genomics Core can simultaneously offer information on the mechanisms of resistance and activity
of these antivirals using sequencing data as a readout. Specifically, we will recover viral whole genomes from
viral isolates subjected to selection with the proposed antiviral compounds during in vitro and in vivo experiments
to determine mechanisms of resistance and activity. In addition, the Genomics Core will enhance rigor,
reproducibility, and generalizability of the proposed studies by ensuring the integrity of viral isolates and
constructs prior to labor-intensive and expensive in vivo experimentation in all Projects. The Core ensures that
the Research Projects can obtain accurate results from high-throughput genomics testing without redundant
effort to enable scientific inquiry into the activity of antivirals against a variety of high consequence RNA viruses.

## Key facts

- **NIH application ID:** 10513939
- **Project number:** 1U19AI171403-01
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Alexander L Greninger
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,841,208
- **Award type:** 1
- **Project period:** 2022-05-16 → 2026-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10513939

## Citation

> US National Institutes of Health, RePORTER application 10513939, Core D - Genomics (1U19AI171403-01). Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/grant/nih/10513939. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*